Skip to content

Effect of Mild Therapeutic Hypothermia on the Doses of Vasopressors and Inotropes in Cardiogenic Shock Complicating Acute Myocardial Infarction

Effect of Mild Therapeutic Hypothermia on the Doses of Vasopressors and Inotropes in Cardiogenic Shock Complicating Acute Myocardial Infarction: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06947616
Enrollment
60
Registered
2025-04-27
Start date
2020-10-01
Completion date
2022-10-01
Last updated
2025-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction, Cardiogenic Shock, Inotropes, Mild Therapeutic Hypothermia, Vasopressors

Brief summary

The study aimed to assess the effects of mild therapeutic hypothermia (MTH) on vasopressors and inotropes in patients with cardiogenic shock (CS) due to acute myocardial infarction (AMI).

Detailed description

Cardiogenic shock (CS) is a condition characterized by a severe lack of blood flow to vital organs caused by primary malfunction of the heart, as described by the European Society of Cardiology (ESC) and the American Heart Association (AHA). Acute myocardial infarction (AMI) is a prevalent etiology of CS, constituting a minimum of 30% of the instances. 50% of CS cases manifest upon hospital admission, whereas the remaining 50% occur after hospital admission.

Interventions

Patients received mild therapeutic hypothermia (MTH) to 33°C for 24-36 h

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age from 50 to 70 years. * Both sexes. * Cardiogenic shock post AMI defined by systolic blood pressure \<90 mm Hg for \>30 minutes or motropes required to maintain a systolic blood pressure \>90 mm Hg in the absence of hypovolemia with signs of pulmonary congestion and signs of impaired organ perfusion defined by at least 1 of the following: altered mental status; cold, clammy skin; urine output \<30 mL/h; or arterial lactate \>2 mmol/L. 2\. Intubated and sedated

Exclusion criteria

1. Self-ventilated 2. Indication for targeted temperature management by current guidelines out of hospital cardiac arrest with return of spontaneous circulation (ROSC)

Design outcomes

Primary

MeasureTime frameDescription
Incidence of stroke30 day after the procedureIncidence of stroke until day 30 was recorded.

Secondary

MeasureTime frameDescription
Duration of mechanical ventilationUp to 7 daysDuration of mechanical ventilation was recorded.
Length of intensive care unit stayUp to 2 weeks after the procedureLength of intensive care unit (ICU) stay refers to the total duration a patient remains in the ICU, beginning from the moment of admission to the ICU until their discharge or transfer to a less intensive care setting, such as a regular hospital ward or home.
Duration of inotropic supportIntraoperativelyDuration of inotropic support was recorded.
Incidence of mortality30 days after the procedureIncidence of mortality was recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026